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Abstract
Background: The placenta is an essential organ that provides nutrients and oxygen to the developing fetus and
removes toxic waste products from the fetal circulation. Maintaining placental blood osmotic pressure and blood
flow is crucial for viable offspring. The renin-angiotensin system (RAS) in the placenta is a key player in the
regulation of maternal-fetal blood flow during pregnancy. Therefore, the aim of this study was to determine if RAS
genes are differentially expressed in mid to late gestation in rat placenta.
Methods: Whole placental tissue samples from pregnant Sprague Dawley rats at embryonic (E) days 14.25, 15.25,
17.25 and 20 (n = 6 for each gestational age) were used for genome-wide gene expression by microarray. RAS
genes with expression differences of >2 fold were further analyzed. Quantitative Real-Time PCR (qPCR) was
performed on independent samples to confirm and validate microarray data. Immunohistochemisty and Western
blotting were performed on a differentially expressed novel RAS pathway gene (ANPEP).
Results: Six out of 17 genes of the RAS pathway were differentially expressed at different gestational ages. Gene
expression of four genes (Angiotensin converting enzyme (Ace), angiotensin converting enzyme 2 (Ace2),
membrane metalloendopeptidase (Mme) and angiotensin II receptor 1A (Agtr1a)) were significantly upregulated at
E20 whereas two others (Thimet oligopeptidase 1 (Thop1) and Alanyl aminopeptidase (Anpep)) were downregulated
at E20 prior to the onset of labour. These changes were confirmed by qPCR. Western blots revealed no overall
differences in ANPEP protein expression in the placentae. Immunohistochemical studies, however, indicated that
the localization of ANPEP differed at E17.25 and E20 as ANPEP localization in the giant trophoblast cell of the
junctional zone was no longer detectable at E20.
Conclusions: The current study investigated the expression of members of the RAS pathway in rat placentae and
observed significantly altered expression of 6 RAS genes at 4 gestational ages. These findings present the need for
further comprehensive investigation of RAS genes in normal and complicated pregnancies.
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Background
The Renin-Angiotensin System (RAS) regulates sodium
and water homeostasis to maintain blood pressure and
fluid balance in all mammals [1, 2]. The complex inte-
gration of actions of circulating maternal RAS in preg-
nancy plays a key role in pregnancy outcome and
maternal health. In human pregnancy, the maternal and
fetal circulating RAS interact with various tissue RASs
(ovarian, intrauterine, and intrarenal) [3]. The intra-
uterine/placental RAS is one of the major extrarenal
RAS in pregnancy [4], regulating maternal-fetal blood
flow and the uteroplacental blood circulation [1, 5].
Other uteroplacental RAS functions may include endo-
metrial regeneration, decidualisation, implantation, pla-
centation, uterine contraction, prostaglandin synthesis,
and estradiol 17 beta secretion [6, 7]. Because its functions
are widespread, dysfunction of the RAS system can lead to
complications such as preeclampsia. Placental RAS is itself
regulated by several hormones including estrogen and
progesterone [8].
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The RAS pathway begins with the biosynthesis of active
enzyme, renin, from its 47 kDa precursor, prorenin [9].
Renin cleaves angiotensinogen (AGT) to form angioten-
sin, AngI [10]. AngI is then converted to AngII by
angiotensin-converting enzyme (ACE) [11, 12]. AngII
binds two endogenous receptors: angiotensin II type 1
and 2 receptors (AT1 and AT2) encoded by genes Agtr1
and Agtr2 respectively [2, 4, 13–15]. Agtr1 has two sub-
types Agtr1a and Agtr1b. AngII is the primary product of
RAS and its activity is terminated by its conversion to
Ang 1–7 by MME, membrane metalloendopeptidase [6].
In the RAS pathway, the majority of AngII functions,
which include vasoconstriction, vascular permeability
and peripheral vascular resistance, stimulation of aldos-
terone synthesis, angiogenesis and cell growth, are medi-
ated by AT1 [6, 15–17]. In contrast, AT2 is involved in
apoptosis, reduction of endothelial cell growth, cell mi-
gration, vasodilation, and reduction of vascular injury [2].
AT2 has been hypothesised to antagonize the effects of
AT1 [9, 18], and hence a distorted balance in the expres-
sion of these proteins may be detrimental to pregnancy
outcomes. Placental RAS maybe involved in preeclampsia
with raised AT1 expression [2]. In human placenta and
placental cell lines, the genes involved in the RAS path-
way have been detected in both early and late gestation
leading to the speculation that it is critical throughout
pregnancy [11]. As there is a paucity of data to de-
monstrate changes to RAS factors change as pregnancy
progresses and in complications of pregnancy. Further
investigation are required to determine the importance of
RAS due to changes in expression and the functional
changes associated.
RAS components have been shown to be localised to
different regions and cell types of the placenta. AT1 has
been mainly localised to human placental syncytiotro-
phoblasts [2]. The vasodilator ACE2 [1] has been de-
tected in endothelium and syncitium (i.e. multinucleated
cells) of labyrinth,, subplacenta (highly vascularised re-
gion, part of chorion found between placental disc and
basal decidua) and giant cells, in guinea pigs [19]. In late
pregnancy, ACE2 is present in the decidual layer and
vascular smooth muscles of arteries modulating placen-
tal blood flow, regulating vascular remodeling, and po-
tentiating trophoblast invasion and decidualisation earlier
in pregnancy [19]. The vasodilator ACE2 has been de-
tected in the endothelium, syncyotiotrophoblast, and
cytotrophoblast, in human placenta tissue [20]. It is also
present in the intravascular trophoblast and decidual layer
and the vascular smooth muscle cells of the umbilical
cord vessels [20]. In rats, the upregulation of ACE2
expression in the placenta and uterus contributed to a
two-fold increase in total ACE2 activity [21]. Interestingly,
although ACE2 expression was upregulated in the rat
uterus, it was downregulated at the implantation site [22].
The maternal diet also modulates ACE2 expression; rat
dams fed a low protein diet had reduced Ace2 mRNA ex-
pression in the placenta leading to fetal growth restriction
[1]. Similar results were also reported in ACE2 knockout
mice [23]. Overall, ACE2 is involved in modulating pla-
cental blood flow, regulating vascular remodeling, and
potentiating trophoblast invasion and decidualisation.
Moreover the formation of new blood vessels have been
affected by the effects of hypoxia in Aminopeptidase-null
mice, Aminopeptidase-N, ANPEP being another member
of the RAS system [24].
In humans, trophoblast invasion, vascular remodel-
ling and proper placentation are critical to determine preg-
nancy outcome. Poor vascular remodelling and trophoblast
invasion can lead to complications such as preeclampsia.
Preeclampsia is associated with short and long term conse-
quences for both the mother and baby including preterm
labour and still birth [14, 25, 26]. Alteration of RAS is
involved in the pathogenesis of preeclampsia [27] indicating
the essential role of RAS for the prevention of pregnancy
complications. Gestational age-related studies of RAS
throughout early, mid and late gestation are limited.
Both systemic and uteroplacental RAS undergo dra-
matic changes during pregnancy. RAS components in
human placenta are expressed from 6 weeks of gestation
[12]. Recent studies on the human placenta compared
the localisation and expression of RAS in early gestation
vs late gestation [9, 18]. These studies showed that RAS
plays a significant role in promoting trophoblast invasion
and angiogenesis and is also linked to expression of
PTGS2, Prostaglandin-Endoperoxide Synthase 2 (an en-
zyme potentially involved in the process of parturition).
RAS components have not been comprehensively
studied in rat placenta from mid to late gestation. This
study specifically aimed to determine gene expression
changes of all 17 genes of the RAS pathway in rat pla-
centae. Four time points were chosen as they cover the
time period from mid gestation to the day prior to
labour onset (E14.25, E15.25, E17.25 and E20). These
investigations are apart of a larger gene expression study
[28, 29]. The rat model allows the study of RAS compe-
nents at time-points (mid to late gestation) difficult to
be obtained from human and unlike in the mouse,
placentation in the rat involves the deep invasion of
trophoblast (i.e. a better model of placentation) [30].
Methods
Animals and diets
Animal experiments were performed at the Department
of Anatomy and Developmental Biology, Monash Uni-
versity (Melbourne, Australia) with the approval of The
School of Biomedical Sciences Animal Ethics Committee
of the Monash University. Experiments were carried out
in accordance with the National Health and Medical
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Research Council of Australia “Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes” (7th edition, 2004).
Sprague Dawley dams were used throughout the study.
Rats were allowed to adapt to the animal house for one
week. Throughout the study, animals were maintained
on a diet of standard chow (19.5 % protein, 7 % total fat
and 16 MJ/Kg digestible energy; Glen Forrest StockFee-
ders WA Rat and Mouse Chow) and water ad libitum
prior to diet onset. Rats were maintained in a light-
controlled environment (12 h light/dark cycle) through-
out this study. Female rats were timed mated in a 3 h
window with male Sprague Dawley rats. This was desig-
nated as Day 0 of pregnancy. The rationale of using a
3 h window for mating time is to reduce variability of
gestational age among the offspring and to maximize the
accuracy in staging of gestation. After mating, dams
were housed individually.
Tissue collection
The formation of the chorioallantoic rat placenta begins
on gestational day 12, and therefore the study begins in
mid-gestation. Pregnant dams were anaesthetized (Iso-
flurane Rhodia Australia P/L, VIC, Australia) and hu-
manely killed at embryonic day (E) 14.25, 15.25, 17.25 or
20 (n = 6 per gestational age). Whole placentae were
collected from the pregnant dams, weighed and then
either snap frozen in liquid nitrogen or fixed in 4 % para-
formaldehyde prior to processing for immunohistochem-
istry analysis. Frozen tissues were stored at −80 °C until
processed and analysed.
RNA isolation
Rat placental tissues were pulverized into a fine powder
using liquid nitrogen and mortar and pestle. Total RNA
was extracted from 30 mg of pulverized frozen placental
tissue n = 6 placentae per gestational age group, using
the AllPrep DNA/RNA Mini Kit (Qiagen) as per manu-
facturers’ instructions. An on-column Dnase1 treatment
step was also carried out in the RNA isolation step to
remove any remaining genomic DNA. Following extrac-
tion, total RNA was quantified via NanoDrop ND-1000
spectrophotometer (Thermo Scientific, DE, USA). RNA
quality was determined with the Agilent 2100 Bioana-
lyzer (VIC, Australia). RNA samples that fulfilled the
following criteria were selected for microarray analysis:
(i) RIN > 8.5; (ii) 260/280 ratio >2; (iii) 260:230 ratio
>2.2. All RNA Integrity Number values were greater
than 8.7.
Microarray analysis using Illumina rat ref arrays
The microarray analysis (cohort 1) was performed as
previously published [28]. In short, 500 ng of total RNA
was converted to double stranded cDNA and this was
used to generate biotinylated cRNA probes using the Illu-
mina TotalPrep RNA Amplification Kit. Biotin-labelled
cRNA were then hybridized to Illumina RatRef-12 Expres-
sion BeadChip (San Diego, CA, USA). Slides were scanned
on a BeadStation 500 System using Beadscan software ver-
sion 3.5.31. No RNA samples were pooled in this analysis,
each placental samples was analyzed independently.
Samples were hybridized into wells at random. The Array
experiment readout was deposited on ArrayExpress and
includes gene expression data from microarray and high
throughput sequencing studies (ArrayExpress Accession
number E-MTAB-1987).
RAS genes from the KEGG Renin Angiotensin System
pathway were studied for differential expression using
SAM (Microarray Software, Stanford University) ana-
lyses, whereby differentially expressed placental genes
(i.e. >2 fold expression change) were identified between
each of the 4 gestational age groups.
Quantitative real-time PCR validation
The RNA was reverse transcribed using the QuantiTect
reverse transcription kit (Qiagen) using 1 μg of RNA per
sample. qPCR (cohort 2) was used to confirm and valid-
ate the expression of Ace, Ace2, Thop1, Mme and Anpep
in placentae that were different from those used for the
microarray analysis. Primers unique for each target gene
were designed by Primer-Blast (NCBI), and covered
exon-exon junctions. The primer sequences are provided
in Table 1.
Immunohistochemistry
Paraffin sections (5 μm, n = 3 sections/gestational age)
were deparaffinized in xylene and rehydrated to water
through a graded alcohol series. Antigen retrieval was
achieved by incubation in citrate buffer (10 mM), pH6 at
120 °C for 30 s and 90 °C for 10 min under higher pres-
sure. Sections were blocked in MACH-1 Background
snipper, provided in the MACH-1™ kit (Biocare Medical).
Sections were incubated with rabbit anti-CD13 (ANPEP)
polyclonal antibody (Abcam Cat no ab108310), prior to
incubation with secondary antibodies conjuagated with
Table 1 Primers used for the qPCR experiments for 6 RAS
genes
Gene Forward (5’-3’) Reverse (5’-3’)
Ace ATTGCAGCCGGGCAACTTTT CGCATTCTCCTCCGTGATGT
Ace2 GAGCCCATATGCCGACCAAA TCTGCCTCCCCAAAAGGAAC
Mme CCGAAATGACCCAATGCTGC TGACCAGCTGAATGGCTTCC
Thop1 ATGCTGGAGAACTGGGTGTG GAAGAGACCTGCATTGGCCT
Anpep AGATTGCCCTGCCTGACTTC GTTGCCAAACCACTGATGGG
Agtr1a GGATTCGTGGCTTGAGTCCT TCGAAATCCACTTGACCTGGTG
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HRP. They were then stained using DAB substrate,
whereby positive staining was identified with a brown
colour. Purified Rabbit IgG (Sigma Aldrich) was used as
a negative isotype control. Sections were counterstained
with Mayers hematoxylin and Leica mounting media was
used to mount the coverslips. Slides were examined
under a microscope (Olympus™).
ANPEP western blots
Protein samples from all four gestational age groups
(n = 6) were used to examine ANPEP protein expression
by Western blotting. All reagents, unless otherwise stated,
were purchased from Life Technologies for use in the
NuPage Bis-Tris Electrophoresis System. Total protein
extracted from rat placental tissue (30 μg) were separated
in NuPage 4–12 % Bis-Tris Precast Gels and transferred
to a polyvinyl difluoride (PVDF) membrane. Membranes
were blocked for 1 h in blocking solution containing
bovine serum albumin powder in Tris Buffered Saline
with 0.001 % Tween 20 (Sigma Aldrich, Castle Hill, NSW,
Australia). Membranes were incubated overnight at 4 °C
with ANPEP (cd-13, Abcam cat no ab108310) (Santa
Cruz Biotechnology) and β-Actin (Sigma-Aldrich)primary
antibodies. Secondary antibodies were purchased from
LI-COR™ Biociences. Odessey® LI-COR™ densitometry was
used to determine changes in ANPEP (normalized to β-
ACTIN protein) in the placental tissues.
Statistical analysis
BioInformatic analyses and statistics
Microarray bioinformatic analysis was initially performed
by using the Illumina Beadstudio and Significance Ana-
lysis of Microarry (SAM, Stanford University) software.
Data were normalized by performing a probe-intensity
transformation and normalization via the Lumi package,
Bioconductor. Following normalization, differentially ex-
pressed placental genes (i.e. >2 fold expression, false dis-
covery rate of <1 %) were identified using SAM and were
subsequently analyzed using Web-based Gene Set Ana-
lysis Toolkit (WebGestalt, http://bioinfo.vanderbilt.edu/
webgestalt/).
Genes were then assigned to their respective func-
tional classes based on the Gene Ontology (GO) data-
base; Renin-Angiotensin KEGG PATHWAY Analysis
Differences in group means were assessed by post-hoc
comparisons (Bonferroni tests).
For the qPCR and Western blots comparison of the four
gestational groups, one-way ANOVA analyses and mul-
tiple comparisons were carried out. Correlation plots for
both Microarray and qPCR on cohort 1 and 2 respectively
were performed using Pearson’s Correlation (Additional
file 1: Figure S1).
Results
Differentially expressed RAS genes
A whole genome microarray was performed [28] to exam-
ine differential gene expression in the rat placenta at ges-
tational ages of E14.25, E15.25, E17.25 and E20 (just prior
to birth). For this study, genes of only the RAS pathways
was specifically analyzed. Genes that demonstrated a >2
fold change (microarray analysis) between gestational
ages were considered to be differentially expressed (Fig. 1).
Six out of 17 RAS genes from the KEGG-RAS signaling
pathway (Ace, Ace2, Thop1, Mme, Anpep, and Agtr1a)
were differentially expressed (Fig. 2a, c, e, g, i, k). The
other 11 genes in the pathway remained unchanged be-
tween the 4 gestational age groups (data not shown). The
expression of Ace, Ace2, Mme and Agtr1a increased with
gestational age whereas, Thop1expression was decreased
with gestational age (Fig. 2). Anpep expression increased
with gestational age and then was downregulated just
prior to labour onset, hence we investigated this further
at the protein level using both Western blots and
immunohistochemistry.
Validation of microarray with qPCR
Microarray results were validated by qPCR by using pla-
centa tissue from an independent cohort of rat dams.
Results for the qPCR (cohort 2) are also shown in Fig. 2
for the 6 differentially expressed RAS genes. Additional
file 1: Figure S1 shows the correlation between Micro-
array and qPCR.
Immunohistochemistry on ANPEP
Anpep gene expression increased from E14.25 to E17.25
and subsequently decreased after E17.25. Immunohisto-
chemistry of ANPEP was performed on paraffin sections
of E17.25 and E20 placentae. ANPEP was localized to
both junctional and labyrinth zones (Fig. 3). In the junc-
tional zone of E20 placentae, the decidual cells and
Giant trophoblast cells had less staining compared to
E17.25 placentae. Labyrinth zone localization of ANPEP
remained relatively unchanged between E17.25 and E20
placentae.
ANPEP Western blots
ANPEP protein expression was identified in the placen-
tae at all four gestational ages E14.25, E15.25, E17.25
and E20. However, no significant differences in protein
expression were observed within the 4 groups (Fig. 4).
Discussion
Global RAS gene expression changes in the whole rat
placenta throughout the four gestational ages E14.25,
E15.25, E17.25 and E20 were studied. Ace, Ace2, Agtr1a
(that have previously been studied in rat placenta), and
three additional RAS genes Thop1, Anpep and Mme were
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significantly differentially expressed throughout mid to
late gestation.
The robustness of the findings in this paper is appar-
ent in that a similar pattern of gene expression of the 6
differentially expressed RAS genes was found in two in-
dependent rat cohorts with different techniques (micro-
array and qPCR, respectively) (Fig. 2). Ace expression
was relatively low at E14.25 and E15.25, increased at
E17.25 and E20. Similar results were observed for Ace2,
Mme, and Agtr1. Consistent with previous studies, these
results show that Ace and Ace2 increase dramatically at
late gestation, indicating that the pathway is highly acti-
vated at this stage of gestation [1, 22, 31], so these embry-
onic days were chosen for study. AngII has previously
been shown to be increased with the advancement of
pregnancy due to enhanced Ace2 expression and activity,
which correlate with elevated placental-fetal blood flow
and rapid fetal growth, especially during mid and late
pregnancy [1]. Dietary manipulations may have a signifi-
cant role in disrupting RAS: RAS function is altered by
changes in sodium intake during pregnancy [32], poten-
tially affecting feto-maternal blood flow and hence fetal
nutrient supply, fetal growth and birth weight [32]. Inter-
estingly, another study showed that mRNA expression of
Ace2 and Agtr1a was significantly reduced in the laby-
rinth zone of Sprague Dawley rats fed a low protein diet
[1]. Overall, these studies show that elevation of AngII
concentration via the expression and activity of ACE and
ACE2 and upregulated AT1 expression are potentially
required to to increase blood flow in the placenta and
therefore may ensure the adequate delivery of nutrients
to the fetus, leading to optimal fetal growth.
Mme (membrane metallo-endopeptidase) is an enzyme
that inactivates RAS by converting AngI to Angiotensin
(1–7). Interestingly, MAS1 receptor gene, Mas-Related
G Protein-Coupled Receptor (angiotensin 1–7 receptor)
expression remained unchanged (Fig. 1). Mme has been
studied in renal, lung and neural tissues, however, very
little is known about its role in the placenta [33]. SNPs
leading to truncations of the Mme gene and the loss of
neutral endopeptidase (NEP) protein are theorised to be
the cause for allo-immunisation during pregnancy [34].
Studies in rat brain and neural tissue as well as in hu-
man endometrium show that hormones can regulate
Fig. 1 The Renin angiotensin system showing differentially expressed genes highlighted in red circles (adapted from the KEGG pathway). Solid
lines and arrows (edges) denote direct relationships and dashed lines and arrows represent indirect relationships predicted and confirmed in the
rat KEGG pathway. Arrows denote directional relationships and lines denote non-directional reported in the KEGG pathway. MME: membrane
metalloendopeptidase; ANPEP: Alanyl aminopeptidase; MAS1: Mas-Related G Protein-Coupled Receptor (angiotensin 1–7 receptor); THOP1: Thimet
oligopeptidase 1; ACE: Angiotensin converting enzyme; ACE2 angiotensin converting enzyme 2, AGTR1 and 2 Angiotensin II receptor 1 and 2
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Fig. 2 Six RAS genes that were studied for their differential expression at four gestational stages. a to l shows gene expression patterns of 6 RAS
genes at E14.25, E15.25, E17.25 and E20 comparing Cohort1 (Microarray) and Cohort 2 (qPCR). Significant across the groups by 1 way ANOVA are
shown in graphs as * = <0.05, ** = <0.01, *** = <0.001, and **** = <0.0001
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Mme expression [35, 36]. Since MME enzyme is an im-
portant player in several tissues and in the RAS pathway,
it is important to study its expression and function in
placenta and pregnancy to elucidate its link to pregnancy
complications.
The results of this study showed that the expression of
another novel gene, Thop1, gradually decreases over time
during pregnancy (from E14.25 to E15.25 and further
decreases at E17.25) and is relatively low at E20 prior to
labour onset. There is a paucity of data on Thop1 ex-
pression and function in the placenta, however in the
brain, a therapeutic potential as an anti-tumour agent
has recently been reported [37, 38].
ANPEP (also known as APN) is an enzyme that select-
ively hydrolyses N terminal acidic amino acids such as
glutamyl and aspartyl residues from peptide or substrate,
and can degrade ANGII to ANGIII in the RAS pathway.
It has also been previously established that ANPEP is
localised to trophoblast, fetal arterioles and venules in the
stem villi of the human placenta. The mRNA, protein and
the activity of ANPEP is known to be higher in human
placentae of pregnancies complicated with preeclampsia
compared to normal pregnacy [39]. In APN-null mice, in-
vestigations on the effect of hypoxic conditions found
marked reductions in formations of new blood vessels
(compared to WT animals), indicating the importance of
this factor in angiogenesis [24]. In the current study,
Anpep gene expression was significantly lower at E20 (just
prior to labour onset). We investigated further the protein
expression of ANPEP to examine if the differences at the
gene expression were detectable at the protein level. Pro-
tein expression of ANPEP (Western blot on whole pla-
cental tissue) did not significantly differ between the four
groups. However, ANPEP localization by immunohisto-
cheisty identified staing differences in E17.25 and E20
placentae, as E17.25 ANPEP localization was identified in
Fig. 3 Immunohistochemistry of ANPEP(CD-13). Junctional zone displaying difference in localization of ANPEP in (panels a to c) E17.25 vs (panels
d to f) E20. DC denotes decidual cells, GC giant trophoblast cells (white arrow), ST spongiotrophoblast layer. Labyrinth zone at E17.25 (panel g)
and E20 (panel h) displaying no difference in ANPEP localization. Black arrows indicate blood vessles within the labyrinth zone. Panel i is a
negative isotype (IgG) of labyrinth zone
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the decidual layer, giant trophoblast cells and the spongio-
trophoblast layer whereasat E20 staining was only visible
in spongiotrophoblast layer (no staining in the decidual
layer and giant cells). No visual differences in the loca-
lization of ANPEP was seen in labyrinth zone of the rat
placentae. In future studies, differences in the protein
expression by Western blot of ANPEP and other mem-
bers of the RAS pathway may need to be investigated in
separated junctional and labyrinth zones to fully elucidate
changes to the protein expressions. Furthermore, immu-
nohistochemical studies (such as those described in this
study) may provide more extensive detail as to the cell
types expressing members of the RAS pathway. The find-
ing of these studies mayallow for more specific investiga-
tions to be performed to the role of RAS pathway
members in angiogenesis as well as the overall import-
ance of this pathway in labour. These finding may also
lead to the development of functional studies ulitising
knockout models in animal models (e.g. mice) of the
relavent RAS factors/pathway members.
The expression of 11 RAS genes whose expression
remained unchanged throughout the four gestational
groups were Agt, Ren, Ctsa, Cpa3, Nln, Cma1, Ctsg,
Enpep, Mas, Agtr2 and Lnpep (data not shown). Further
studies will be required to study these genes at the
protein level and also comparing several regions of the
rat placenta.
Many studies have indicated that RAS dysfunction is
associated withpregnancy complications such as pre-
eclampsia [25]. Normal placentataion involves tropho-
blast invasion of maternal decidua and remodelling of
spiral arteries (replacement of smooth muscle cell layer
with fibrinoid material) which causes vessels to increase
in diameter allowing for increased blood flow into the
placenta [40]. Abnormal placentation can lead to preg-
nancy complications such as preeclamsia. Preeclampsia
is associated with shallow trophoblast invasion of the ma-
ternal spiral arteries in the endometrium of the uterus,
leading to improper remodelling of the uterine spiral
arteries [4, 31, 41]. In preeclampsia, increased sensitivity
to Ang II (important in blood flow maintenance) has
been documented and this phenomenon may be devel-
oped before clinical manifestations of the diesease [25].
Women with preeclampsia have been seen to have lower
circulating levels of RAS factors, however, AngII levels,
angiotensinogen and Agtr1 receptor mRNA is increased
Fig. 4 Western Blot results for ANPEP (CD-13). a Protein expression by Western blots displayed no significant differences across the four gestational
ages by 1 way ANOVA- Multiple Comparisons. b Samples in order from left to right; E14.25 n = 6, E115.25 n = 5, E17.25 n = 6 and E20 n = 6
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in placentae of preeclamptic women [41]. Further investiga-
tions are required in normal and complicated pregnancies
to fully elucidate the role of RAS in maintaining a healthy
pregnancy or contributing to pregnancy complications.
Conclusions
Adequate blood flow in the placenta is vital for the main-
tenance of placental function, development and fetal
growth, maintenance and development. The intrauterine/
placental RAS is important in pregnancy, regulating
maternal-fetal blood flow and the uteroplacental blood
circulation. The current study investigated the expression
of members of the RAS pathway in relatively normal rat
placentae at different gestational ages. Six of the 17 RAS
genes were differentially expressed in the rat placenta of
4 different gestational age groups by microarray and the
differernatial expressions validated by qPCR. Immunohis-
tochemical analysis of ANPEP identified differences in
localization at E20 compared to E17.25 rat placentae.
These findings present the need for further comprehen-
sive investigations of RAS genes, specific placental locali-
zations and functional studies in normal and complicated
pregnancies.
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